Remove Aging and mental health Remove Personality disorders Remove Technology
article thumbnail

99 Pubs and Zero Followers? Psychiatric Leadership in the Age of Influencers

Psychiatric Times

Psychiatric Leadership in the Age of Influencers Author(s): Raina Aggarwal, MD Social media shapes mental health discourse, but misinformation and self-diagnosis risks arise as non-professionals dominate the conversation. A larger audience can potentially relate to and benefit from information about mental health.

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

Trontinemab showed significant amyloid plaque reduction in Alzheimer's, validating Brainshuttle technology and prompting a phase 3 study. MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Results are expected in 2026.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intergenerational Gaps and the Role of Technology in Psychiatric Leadership: A Trainee’s Perspective

Psychiatric Times

Technology offers benefits like enhanced education but poses challenges such as reduced human connection and ethical concerns. Effective psychiatric leadership requires balancing generational and technological dynamics to foster collaboration and innovation.

article thumbnail

FDA Advisory Committee Votes Against Recommending Brexpiprazole Plus Sertraline for PTSD

Psychiatric Times

The age group of 39-50 has the highest prevalence, and women are 2 times more likely to have PTSD. The enrollment criteria were generally consistent across the 3 studies: participants were 18-65 years of age and had a diagnosis of PTSD, defined by the DSM-5 and confirmed by the Mini International Neuropsychiatric Interview.

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.”

article thumbnail

Cingulate Receives $4.3 Million PDUFA Fee Waiver for ADHD Treatment, CTx-1301

Psychiatric Times

CTx-1301 uses Precision Timed Release Technology for trimodal, extended-release dexmethylphenidate, ensuring rapid onset and full-day efficacy. Million PDUFA Fee Waiver for ADHD Treatment, CTx-1301 Author(s): Leah Kuntz Key Takeaways Cingulate's PDUFA fee waiver saves $4.3

article thumbnail

Will Retirement of Mental Health Professionals Escalate?

Psychiatric Times

The federal government has made significant cuts in mental health services at a time when mental health disorders and disruptions are increasing. He is an advocate and activist for mental health issues related to climate instability, physician burnout, and xenophobia. Author(s): H.